{"transactions":[{"id":505,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-02T20:16:37.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":644,"price":9.7,"value":6246.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500."}],"balance_after":1340419,"source":{"system":"sec-edgar","filing":"0000882796-26-000065","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385496/000088279626000065/form4.xml","form_type":"4"}},{"id":738598,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2026-06-15T20:10:23.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":33540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":33540,"derivative":{"exercise_price":8.5,"exercise_date":"2027-06-11","expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":33540},"source":{"system":"sec-edgar","filing":"0000882796-26-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000039/form4.xml","form_type":"4"}},{"id":738597,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-15T20:10:23.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":1339775,"source":{"system":"sec-edgar","filing":"0000882796-26-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000039/form4.xml","form_type":"4"}},{"id":756036,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-06-02T20:14:06.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":631,"price":8.91,"value":5622.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250."}],"balance_after":1324481,"source":{"system":"sec-edgar","filing":"0000882796-26-000031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000031/form4.xml","form_type":"4"}},{"id":871221,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2026-03-03T21:34:13.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":305995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":0,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":305995},"source":{"system":"sec-edgar","filing":"0000882796-26-000011","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000011/form4.xml","form_type":"4"}},{"id":871220,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-03T21:34:13.000Z","date":"2026-03-02","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":305995,"price":8.64,"value":2643796.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":1323850,"source":{"system":"sec-edgar","filing":"0000882796-26-000011","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000011/form4.xml","form_type":"4"}},{"id":871219,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-03T21:34:13.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":305995,"price":3.22,"value":985303.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person."}],"balance_after":1629845,"source":{"system":"sec-edgar","filing":"0000882796-26-000011","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000011/form4.xml","form_type":"4"}},{"id":871218,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-03-03T21:34:13.000Z","date":"2026-02-27","kind":"grant","planned":true,"acquired":true,"shares":421,"price":8.75,"value":3683.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375."}],"balance_after":1323850,"source":{"system":"sec-edgar","filing":"0000882796-26-000011","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279626000011/form4.xml","form_type":"4"}},{"id":960282,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-23T21:13:58.000Z","date":"2025-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":61793,"price":7.41,"value":457886.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person."}],"balance_after":1323429,"source":{"system":"sec-edgar","filing":"0000882796-25-000045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000045/form4.xml","form_type":"4"}},{"id":962581,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:21:58.000Z","date":"2025-12-18","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, the reporting person gifted 10,000 shares held directly by him to each of the Caroline Stonehouse Irrevocable Trust and the Samuel Stonehouse Irrevocable Trust."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001171843-25-008039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325008039/ownership.xml","form_type":"4"}},{"id":962580,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:21:58.000Z","date":"2025-12-18","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, the reporting person gifted 10,000 shares held directly by him to each of the Caroline Stonehouse Irrevocable Trust and the Samuel Stonehouse Irrevocable Trust."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001171843-25-008039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325008039/ownership.xml","form_type":"4"}},{"id":962579,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:21:58.000Z","date":"2025-12-18","kind":"gift","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, the reporting person gifted 10,000 shares held directly by him to each of the Caroline Stonehouse Irrevocable Trust and the Samuel Stonehouse Irrevocable Trust."}],"balance_after":1385222,"source":{"system":"sec-edgar","filing":"0001171843-25-008039","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325008039/ownership.xml","form_type":"4"}},{"id":968338,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-16T21:09:05.000Z","date":"2025-12-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":27368,"price":7.57,"value":207175.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person."}],"balance_after":1405222,"source":{"system":"sec-edgar","filing":"0000882796-25-000031","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000088279625000031/form4.xml","form_type":"4"}},{"id":1000541,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-13T21:00:11.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47730,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time.  In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,"},{"field":"security","element":"securityTitle","label":"F4","text":"(Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time.  In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option provided for vesting in 36 substantially equal monthly installments from April 28, 2025."}],"balance_after":0,"derivative":{"exercise_price":19.81,"expiration_date":"2035-04-27","underlying":"Common Stock","underlying_shares":47730},"source":{"system":"sec-edgar","filing":"0001193125-25-280798","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280798/ownership.xml","form_type":"4"}},{"id":1000540,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-11-13T21:00:11.000Z","date":"2025-11-13","kind":"grant","planned":false,"acquired":true,"shares":2688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  The cash payment and the CVRs are not subject to vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  The cash payment and the CVRs are not subject to vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  The cash payment and the CVRs are not subject to vesting."}],"balance_after":2688,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2688},"source":{"system":"sec-edgar","filing":"0001193125-25-280798","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280798/ownership.xml","form_type":"4"}},{"id":1000539,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-13T21:00:11.000Z","date":"2025-11-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the \"Merger Agreement\"), by and among Metsera, Inc. (the \"Company\"), Pfizer Inc., a Delaware corporation (\"Parent\"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the \"Merger Sub\"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the \"Merger\").  At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the \"Common Stock\") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the \"Closing Amount\"), net of all applicable withholding taxes, plus"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a \"CVR\") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On November 12, 2025, the Reporting Person was granted restricted stock units (\"RSUs\") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock.  The RSUs vest in 36 substantially equal monthly installments from November 12, 2025.  Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU.  The cash payment and the CVRs are not subject to vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-280798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000119312525280798/ownership.xml","form_type":"4"}},{"id":1163485,"issuer":{"id":73102,"kind":"organization","name":"Metsera, Inc.","symbol":"MTSR"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-30T21:11:04.000Z","date":"2025-04-28","kind":"grant","planned":false,"acquired":true,"shares":47730,"price":19.81,"value":945531.3,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and become exercisable in 36 substantially equal monthly installments after the date of grant, such that the option will be vested in full on the third anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":47730,"derivative":{"exercise_price":19.81,"expiration_date":"2035-04-27","underlying":"Common Stock","underlying_shares":47730},"source":{"system":"sec-edgar","filing":"0000950170-25-061391","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040807/000095017025061391/ownership.xml","form_type":"4"}},{"id":1323458,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2024-12-23T21:01:43.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":750250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":750250,"derivative":{"exercise_price":7.39,"exercise_date":"2025-12-19","expiration_date":"2034-12-19","underlying":"Common Stock","underlying_shares":750250},"source":{"system":"sec-edgar","filing":"0001127602-24-029948","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029948/form4.xml","form_type":"4"}},{"id":1323457,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:43.000Z","date":"2024-12-20","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 20, 2024, the Reporting Person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001127602-24-029948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029948/form4.xml","form_type":"4"}},{"id":1323456,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:43.000Z","date":"2024-12-20","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 20, 2024, the Reporting Person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001127602-24-029948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029948/form4.xml","form_type":"4"}},{"id":1323455,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:43.000Z","date":"2024-12-20","kind":"gift","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 20, 2024, the Reporting Person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":1429109,"source":{"system":"sec-edgar","filing":"0001127602-24-029948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029948/form4.xml","form_type":"4"}},{"id":1323454,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:43.000Z","date":"2024-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":14010,"price":7.39,"value":103533.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person."}],"balance_after":1449109,"source":{"system":"sec-edgar","filing":"0001127602-24-029948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029948/form4.xml","form_type":"4"}},{"id":1323453,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-23T21:01:43.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":362100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":1463119,"source":{"system":"sec-edgar","filing":"0001127602-24-029948","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029948/form4.xml","form_type":"4"}},{"id":1329829,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-12-17T21:16:06.000Z","date":"2024-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":27525,"price":7.53,"value":207263.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person."}],"balance_after":1101019,"source":{"system":"sec-edgar","filing":"0001127602-24-029592","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224029592/form4.xml","form_type":"4"}},{"id":1516569,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-05-15T11:08:16.000Z","date":"2024-05-13","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":5.55,"value":166500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.34 to $5.68. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote."}],"balance_after":1127770,"source":{"system":"sec-edgar","filing":"0001127602-24-015365","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224015365/form4.xml","form_type":"4"}},{"id":1689385,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-01-04T21:31:49.000Z","date":"2024-01-03","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 3, 2024, the reporting person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001127602-24-000832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224000832/form4.xml","form_type":"4"}},{"id":1689384,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-01-04T21:31:49.000Z","date":"2024-01-03","kind":"gift","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 3, 2024, the reporting person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001127602-24-000832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224000832/form4.xml","form_type":"4"}},{"id":1689383,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-01-04T21:31:49.000Z","date":"2024-01-03","kind":"gift","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 3, 2024, the reporting person gifted 10,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":1094770,"source":{"system":"sec-edgar","filing":"0001127602-24-000832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224000832/form4.xml","form_type":"4"}},{"id":1703751,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-12-20T21:40:30.000Z","date":"2023-12-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":14089,"price":6.05,"value":85238.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":1114770,"source":{"system":"sec-edgar","filing":"0001127602-23-030187","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223030187/form4.xml","form_type":"4"}},{"id":1708117,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2023-12-18T21:43:41.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":595000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":595000,"derivative":{"exercise_price":6.43,"exercise_date":"2024-12-14","expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":595000},"source":{"system":"sec-edgar","filing":"0001127602-23-029835","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029835/form4.xml","form_type":"4"}},{"id":1708116,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-12-18T21:43:41.000Z","date":"2023-12-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":13592,"price":6.43,"value":87396.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person."}],"balance_after":1128859,"source":{"system":"sec-edgar","filing":"0001127602-23-029835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029835/form4.xml","form_type":"4"}},{"id":1708115,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-12-18T21:43:41.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":1142451,"source":{"system":"sec-edgar","filing":"0001127602-23-029835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223029835/form4.xml","form_type":"4"}},{"id":1855073,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-06-15T20:50:12.000Z","date":"2023-06-13","kind":"gift","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reflects a gift by the reporting person of shares of the issuer's common stock to a charitable donor advised fund."}],"balance_after":1014794,"source":{"system":"sec-edgar","filing":"0001171843-23-003946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000117184323003946/ownership.xml","form_type":"4"}},{"id":1940707,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2023-03-23T20:40:35.000Z","date":"2023-03-21","kind":"exercise","planned":false,"acquired":false,"shares":31055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person engaged in a non-market, cash exercise and hold transaction to purchase shares of issuer common stock underlying stock options that were originally granted to the reporting person on May 23, 2016. No sales of the issuer's common stock have occurred as part of this transaction."}],"balance_after":305995,"derivative":{"exercise_price":3.22,"exercise_date":"2017-05-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":31055},"source":{"system":"sec-edgar","filing":"0001127602-23-011193","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223011193/form4.xml","form_type":"4"}},{"id":1940706,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-23T20:40:35.000Z","date":"2023-03-21","kind":"exercise","planned":false,"acquired":true,"shares":31055,"price":3.22,"value":99997.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person engaged in a non-market, cash exercise and hold transaction to purchase shares of issuer common stock underlying stock options that were originally granted to the reporting person on May 23, 2016. No sales of the issuer's common stock have occurred as part of this transaction."}],"balance_after":1039794,"source":{"system":"sec-edgar","filing":"0001127602-23-011193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223011193/form4.xml","form_type":"4"}},{"id":2037247,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2023-02-02T22:20:01.000Z","date":"2023-02-01","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on August 8, 2013 and would have expired on August 8, 2023. The shares sold subsequent to the exercise of such options represent less than 2% of the reporting person's holdings of the issuer's securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested upon the achievement of performance-based vesting criteria with respect to 25,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020."}],"balance_after":0,"derivative":{"exercise_price":5.45,"expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001127602-23-003172","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223003172/form4.xml","form_type":"4"}},{"id":2037246,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-02T22:20:01.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":100000,"price":10.38,"value":1038000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on August 8, 2013 and would have expired on August 8, 2023. The shares sold subsequent to the exercise of such options represent less than 2% of the reporting person's holdings of the issuer's securities."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.22 to $10.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":1008739,"source":{"system":"sec-edgar","filing":"0001127602-23-003172","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223003172/form4.xml","form_type":"4"}},{"id":2037245,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-02T22:20:01.000Z","date":"2023-02-01","kind":"exercise","acquired":true,"shares":100000,"price":5.45,"value":545000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on August 8, 2013 and would have expired on August 8, 2023. The shares sold subsequent to the exercise of such options represent less than 2% of the reporting person's holdings of the issuer's securities."}],"balance_after":1108739,"source":{"system":"sec-edgar","filing":"0001127602-23-003172","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223003172/form4.xml","form_type":"4"}},{"id":2037244,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-02T22:20:01.000Z","date":"2022-12-29","kind":"gift","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 29, 2022, the reporting person gifted 5,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001127602-23-003172","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223003172/form4.xml","form_type":"4"}},{"id":2037243,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-02T22:20:01.000Z","date":"2022-12-29","kind":"gift","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 29, 2022, the reporting person gifted 5,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001127602-23-003172","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223003172/form4.xml","form_type":"4"}},{"id":2037242,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-02-02T22:20:01.000Z","date":"2022-12-29","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 29, 2022, the reporting person gifted 5,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust."}],"balance_after":1008739,"source":{"system":"sec-edgar","filing":"0001127602-23-003172","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223003172/form4.xml","form_type":"4"}},{"id":2061934,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T13:11:55.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":121452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date."}],"balance_after":204086,"source":{"system":"sec-edgar","filing":"0001628280-23-000419","document":"wf-form4_167294230117045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023000419/wf-form4_167294230117045.xml","form_type":"4"}},{"id":2066202,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-04T20:08:09.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":60580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment is being filed to correct the mathematical error in the total amount of securities beneficially owned following the reported transaction on the original Form 4 filed with the SEC on September 2, 2022."}],"balance_after":82634,"source":{"system":"sec-edgar","filing":"0001628280-23-000354","document":"wf-form4a_167288087288104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023000354/wf-form4a_167288087288104.xml","form_type":"4/A","original_submission_date":"2022-09-02"}},{"id":2079145,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-21T21:38:35.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":595000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":595000,"derivative":{"exercise_price":10.63,"exercise_date":"2023-12-19","expiration_date":"2032-12-19","underlying":"Common Stock","underlying_shares":595000},"source":{"system":"sec-edgar","filing":"0001127602-22-028080","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028080/form4.xml","form_type":"4"}},{"id":2079144,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-21T21:38:35.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":1015230,"source":{"system":"sec-edgar","filing":"0001127602-22-028080","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222028080/form4.xml","form_type":"4"}},{"id":2082614,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-19T22:09:01.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":14100,"price":10.9,"value":153690.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 30,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.39. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":887730,"source":{"system":"sec-edgar","filing":"0001127602-22-027894","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222027894/form4.xml","form_type":"4"}},{"id":2099102,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-02T23:33:59.000Z","date":"2022-12-02","kind":"exercise","acquired":false,"shares":82656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities."}],"balance_after":0,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":82656},"source":{"system":"sec-edgar","filing":"0001127602-22-026832","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026832/form4.xml","form_type":"4"}},{"id":2099101,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-12-02T23:33:59.000Z","date":"2022-12-01","kind":"exercise","acquired":false,"shares":214917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities."}],"balance_after":82656,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":214917},"source":{"system":"sec-edgar","filing":"0001127602-22-026832","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026832/form4.xml","form_type":"4"}},{"id":2099100,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-02T23:33:59.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":82656,"price":12.8,"value":1057996.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":901830,"source":{"system":"sec-edgar","filing":"0001127602-22-026832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026832/form4.xml","form_type":"4"}},{"id":2099099,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-02T23:33:59.000Z","date":"2022-12-02","kind":"exercise","acquired":true,"shares":82656,"price":1.42,"value":117371.52,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities."}],"balance_after":984486,"source":{"system":"sec-edgar","filing":"0001127602-22-026832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026832/form4.xml","form_type":"4"}},{"id":2099098,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-02T23:33:59.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":214917,"price":13,"value":2793921.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.75 to $13.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":901830,"source":{"system":"sec-edgar","filing":"0001127602-22-026832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026832/form4.xml","form_type":"4"}},{"id":2099097,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-12-02T23:33:59.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":214917,"price":1.42,"value":305182.14,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities."}],"balance_after":1116747,"source":{"system":"sec-edgar","filing":"0001127602-22-026832","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222026832/form4.xml","form_type":"4"}},{"id":2167225,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-02T10:26:46.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":60580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date."}],"balance_after":103688,"source":{"system":"sec-edgar","filing":"0001628280-22-024213","document":"wf-form4_166212879414951.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022024213/wf-form4_166212879414951.xml","form_type":"4"}},{"id":2168802,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-09-01T16:39:15.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":21054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs were granted on January 4, 2021 and vested in full upon the one year anniversary."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs were granted on January 4, 2021 and vested in full upon the one year anniversary."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022."}],"balance_after":21054,"derivative":{"underlying":"Common Stock","underlying_shares":21054},"source":{"system":"sec-edgar","filing":"0001628280-22-024156","document":"wf-form4a_166206473196248.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022024156/wf-form4a_166206473196248.xml","form_type":"4/A","original_submission_date":"2022-01-06"}},{"id":2168801,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-01T16:39:15.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":21054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment is being filed to correct the typographical error in the amount of converted RSUs on the original Form 4 filed with the SEC on January 6, 2022."}],"balance_after":22054,"source":{"system":"sec-edgar","filing":"0001628280-22-024156","document":"wf-form4a_166206473196248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022024156/wf-form4a_166206473196248.xml","form_type":"4/A","original_submission_date":"2022-01-06"}},{"id":2229636,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T14:48:17.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":1.11,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-22-017340","document":"wf-form4_165540528204428.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022017340/wf-form4_165540528204428.xml","form_type":"4"}},{"id":2436233,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2022-01-13T21:45:25.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":184000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":4.73,"exercise_date":"2013-03-01","expiration_date":"2022-03-01","underlying":"Common Stock","underlying_shares":184000},"source":{"system":"sec-edgar","filing":"0001127602-22-001458","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222001458/form4.xml","form_type":"4"}},{"id":2436232,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-01-13T21:45:25.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":184000,"price":15.04,"value":2767360.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":901602,"source":{"system":"sec-edgar","filing":"0001127602-22-001458","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222001458/form4.xml","form_type":"4"}},{"id":2436231,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-01-13T21:45:25.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":184000,"price":4.73,"value":870320.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.  The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022."}],"balance_after":1085602,"source":{"system":"sec-edgar","filing":"0001127602-22-001458","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222001458/form4.xml","form_type":"4"}},{"id":2441124,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-01-06T09:40:27.000Z","date":"2022-01-04","kind":"exercise","acquired":false,"shares":21504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in full upon the one year anniversary of the grant date on January 4, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21504},"source":{"system":"sec-edgar","filing":"0001628280-22-000413","document":"wf-form4_164148001306460.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022000413/wf-form4_164148001306460.xml","form_type":"4"}},{"id":2441123,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-06T09:40:27.000Z","date":"2022-01-04","kind":"exercise","acquired":true,"shares":21504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."}],"balance_after":22504,"source":{"system":"sec-edgar","filing":"0001628280-22-000413","document":"wf-form4_164148001306460.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828022000413/wf-form4_164148001306460.xml","form_type":"4"}},{"id":2470707,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2021-12-16T21:53:41.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":574500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":574500,"derivative":{"exercise_price":11.43,"exercise_date":"2022-12-14","expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":574500},"source":{"system":"sec-edgar","filing":"0001127602-21-031116","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031116/form4.xml","form_type":"4"}},{"id":2470706,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-16T21:53:41.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":123000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":901602,"source":{"system":"sec-edgar","filing":"0001127602-21-031116","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031116/form4.xml","form_type":"4"}},{"id":2470705,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-16T21:53:41.000Z","date":"2021-09-01","kind":"gift","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects a gift of shares by the reporting person to the Caroline Stonehouse Irrevocable Trust."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-21-031116","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031116/form4.xml","form_type":"4"}},{"id":2470704,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-16T21:53:41.000Z","date":"2021-09-01","kind":"gift","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a gift of shares by the reporting person to the Samuel Stonehouse Irrevocable Trust."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-21-031116","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031116/form4.xml","form_type":"4"}},{"id":2470703,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-16T21:53:41.000Z","date":"2021-09-01","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects a gift of shares by the reporting person to the Caroline Stonehouse Irrevocable Trust."}],"balance_after":778602,"source":{"system":"sec-edgar","filing":"0001127602-21-031116","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031116/form4.xml","form_type":"4"}},{"id":2470702,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-12-16T21:53:41.000Z","date":"2021-09-01","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects a gift of shares by the reporting person to the Samuel Stonehouse Irrevocable Trust."}],"balance_after":783602,"source":{"system":"sec-edgar","filing":"0001127602-21-031116","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221031116/form4.xml","form_type":"4"}},{"id":2639153,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-07T20:30:21.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6500,"derivative":{"exercise_price":3.05,"exercise_date":"2022-06-15","expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001209191-21-045947","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000120919121045947/doc4.xml","form_type":"4"}},{"id":2919452,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-01-05T18:40:55.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":21054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (the \"RSU\") represents a contingent right to receive one share of BLCM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest in full upon the one year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs will vest in full upon the one year anniversary of the date of grant."}],"balance_after":21054,"derivative":{"underlying":"Common Stock","underlying_shares":21054},"source":{"system":"sec-edgar","filing":"0001628280-21-000101","document":"wf-form4_160989004218833.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828021000101/wf-form4_160989004218833.xml","form_type":"4"}},{"id":2941053,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-17T21:20:55.000Z","date":"2020-12-15","kind":"grant","acquired":true,"shares":870000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":870000,"derivative":{"exercise_price":8.31,"exercise_date":"2021-12-15","expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":870000},"source":{"system":"sec-edgar","filing":"0001127602-20-031780","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031780/form4.xml","form_type":"4"}},{"id":2941052,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-17T21:20:55.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":134278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020."}],"balance_after":1,"derivative":{"exercise_price":4.15,"exercise_date":"2012-03-01","expiration_date":"2021-03-01","underlying":"Common Stock","underlying_shares":134278},"source":{"system":"sec-edgar","filing":"0001127602-20-031780","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031780/form4.xml","form_type":"4"}},{"id":2941051,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-12-17T21:20:55.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":134278,"price":8.32,"value":1117192.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.18 to $8.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":784086,"source":{"system":"sec-edgar","filing":"0001127602-20-031780","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031780/form4.xml","form_type":"4"}},{"id":2941050,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-12-17T21:20:55.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":134278,"price":4.15,"value":557253.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020."}],"balance_after":918364,"source":{"system":"sec-edgar","filing":"0001127602-20-031780","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220031780/form4.xml","form_type":"4"}},{"id":2955696,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-07T21:16:50.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":157250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020."}],"balance_after":157250,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-18","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":157250},"source":{"system":"sec-edgar","filing":"0001127602-20-030693","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030693/form4.xml","form_type":"4"}},{"id":2955695,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-12-07T21:16:50.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020."}],"balance_after":25000,"derivative":{"exercise_price":5.45,"exercise_date":"2020-12-03","expiration_date":"2023-08-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001127602-20-030693","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220030693/form4.xml","form_type":"4"}},{"id":3108577,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-16T16:46:36.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date."}],"balance_after":6500,"derivative":{"exercise_price":8.42,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001628280-20-009546","document":"wf-form4_159234037743780.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828020009546/wf-form4_159234037743780.xml","form_type":"4"}},{"id":3147969,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-05-15T20:20:44.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":157250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On May 13, 2020, the Board of Directors determined that the initial data from part 3 of the BCX9930 phase 1 clinical trial represented successful results from a proof of concept study of BCX9930 and, as a result, that one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020."}],"balance_after":157250,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-18","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":157250},"source":{"system":"sec-edgar","filing":"0001127602-20-016759","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220016759/form4.xml","form_type":"4"}},{"id":3250614,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-25T21:25:42.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":27140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to Mr. Stonehouse in January 2015 has been met. Therefore, 20% of the performance-based stock options vested."}],"balance_after":27140,"derivative":{"exercise_price":12.16,"exercise_date":"2020-02-21","expiration_date":"2025-01-01","underlying":"Common Stock","underlying_shares":27140},"source":{"system":"sec-edgar","filing":"0001127602-20-007615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220007615/form4.xml","form_type":"4"}},{"id":3264770,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2020-02-19T21:53:37.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":47495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On February 18, 2019, the company announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to Mr. Stonehouse in January 2015 has been met. Therefore, 35% of the performance-based stock options vested."}],"balance_after":47495,"derivative":{"exercise_price":12.16,"exercise_date":"2020-02-14","expiration_date":"2025-01-01","underlying":"Common Stock","underlying_shares":47495},"source":{"system":"sec-edgar","filing":"0001127602-20-006477","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220006477/form4.xml","form_type":"4"}},{"id":3335647,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2019-12-19T22:34:00.000Z","date":"2019-12-17","kind":"grant","acquired":true,"shares":314500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":314500,"derivative":{"exercise_price":3.23,"exercise_date":"2020-12-17","expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":314500},"source":{"system":"sec-edgar","filing":"0001127602-19-035542","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219035542/form4.xml","form_type":"4"}},{"id":3369159,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-11-18T21:17:57.000Z","date":"2019-11-18","kind":"purchase","acquired":true,"shares":50000,"price":1.45,"value":72500.0,"ownership":{"direct":true},"balance_after":778086,"source":{"system":"sec-edgar","filing":"0001127602-19-033035","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219033035/form4.xml","form_type":"4"}},{"id":3489286,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T16:03:53.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date."}],"balance_after":25000,"derivative":{"exercise_price":1.96,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001358403-19-000091","document":"wf-form4_156054261591323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000135840319000091/wf-form4_156054261591323.xml","form_type":"4"}},{"id":3710942,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-01-03T21:27:38.000Z","date":"2019-01-01","kind":"tax_withholding","acquired":false,"shares":3568,"price":8.07,"value":28793.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":724106,"source":{"system":"sec-edgar","filing":"0001127602-19-000701","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219000701/form4.xml","form_type":"4"}},{"id":3722614,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-12-21T21:05:09.000Z","date":"2018-12-20","kind":"grant","acquired":true,"shares":675000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":675000,"derivative":{"exercise_price":7.06,"exercise_date":"2019-12-20","expiration_date":"2028-12-20","underlying":"Common Stock","underlying_shares":675000},"source":{"system":"sec-edgar","filing":"0001127602-18-037163","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218037163/form4.xml","form_type":"4"}},{"id":3742443,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-12-06T21:34:07.000Z","date":"2018-12-03","kind":"exercise","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018."}],"balance_after":0,"derivative":{"exercise_price":1.2,"exercise_date":"2010-03-02","expiration_date":"2019-03-02","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001127602-18-035394","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035394/form4.xml","form_type":"4"}},{"id":3742442,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-06T21:34:07.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":80000,"price":9.12,"value":729600.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.93 to $9.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":727674,"source":{"system":"sec-edgar","filing":"0001127602-18-035394","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035394/form4.xml","form_type":"4"}},{"id":3742441,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-12-06T21:34:07.000Z","date":"2018-12-03","kind":"exercise","acquired":true,"shares":80000,"price":1.2,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2018."}],"balance_after":807674,"source":{"system":"sec-edgar","filing":"0001127602-18-035394","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218035394/form4.xml","form_type":"4"}},{"id":3766408,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-13T16:01:27.000Z","date":"2018-11-09","kind":"purchase","acquired":true,"shares":10000,"price":4.56,"value":45600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001358403-18-000102","document":"wf-form4_154214286960560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000135840318000102/wf-form4_154214286960560.xml","form_type":"4"}},{"id":3890390,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-18T16:31:13.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2019 Annual Meeting of stockholders."}],"balance_after":10000,"derivative":{"exercise_price":9.8,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001358403-18-000061","document":"wf-form4_152935385344279.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000135840318000061/wf-form4_152935385344279.xml","form_type":"4"}},{"id":3924885,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-05-21T13:31:40.000Z","date":"2018-05-17","kind":"exercise","acquired":false,"shares":70427,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":297573,"derivative":{"exercise_price":1.42,"exercise_date":"2014-01-01","expiration_date":"2023-01-01","underlying":"Common Stock","underlying_shares":70427},"source":{"system":"sec-edgar","filing":"0001127602-18-018216","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218018216/form4.xml","form_type":"4"}},{"id":3924884,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-05-21T13:31:40.000Z","date":"2018-05-17","kind":"exercise","acquired":true,"shares":70427,"price":1.42,"value":100006.34,"ownership":{"direct":true},"balance_after":725519,"source":{"system":"sec-edgar","filing":"0001127602-18-018216","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218018216/form4.xml","form_type":"4"}},{"id":4021930,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2018-03-02T19:23:25.000Z","date":"2018-02-28","kind":"exercise","acquired":false,"shares":56949,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.26,"exercise_date":"2009-03-14","expiration_date":"2018-03-14","underlying":"Common Stock","underlying_shares":56949},"source":{"system":"sec-edgar","filing":"0001127602-18-009568","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218009568/form4.xml","form_type":"4"}},{"id":4021929,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-02T19:23:25.000Z","date":"2018-02-28","kind":"tax_withholding","acquired":false,"shares":43224,"price":4.97,"value":214823.28,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise."}],"balance_after":655092,"source":{"system":"sec-edgar","filing":"0001127602-18-009568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218009568/form4.xml","form_type":"4"}},{"id":4021928,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-03-02T19:23:25.000Z","date":"2018-02-28","kind":"exercise","acquired":true,"shares":56949,"price":3.26,"value":185653.74,"ownership":{"direct":true},"balance_after":698316,"source":{"system":"sec-edgar","filing":"0001127602-18-009568","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218009568/form4.xml","form_type":"4"}},{"id":4092899,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-01-23T14:03:38.000Z","date":"2018-01-20","kind":"tax_withholding","acquired":false,"shares":9584,"price":5.59,"value":53574.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014."}],"balance_after":638367,"source":{"system":"sec-edgar","filing":"0001127602-18-002228","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218002228/form4.xml","form_type":"4"}},{"id":4114664,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2018-01-03T13:59:35.000Z","date":"2018-01-01","kind":"tax_withholding","acquired":false,"shares":2716,"price":4.91,"value":13335.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015."}],"balance_after":647951,"source":{"system":"sec-edgar","filing":"0001127602-18-000295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218000295/form4.xml","form_type":"4"}},{"id":4122957,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-12-22T15:06:36.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":300000,"derivative":{"exercise_price":5.04,"exercise_date":"2018-12-20","expiration_date":"2027-12-20","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001127602-17-035395","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217035395/form4.xml","form_type":"4"}},{"id":4218734,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-09-05T19:26:27.000Z","date":"2017-08-31","kind":"grant","acquired":true,"shares":40710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded to the reporting person in January 2015 has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017."}],"balance_after":40710,"derivative":{"exercise_price":12.16,"exercise_date":"2017-08-31","expiration_date":"2025-01-01","underlying":"Common Stock","underlying_shares":40710},"source":{"system":"sec-edgar","filing":"0001127602-17-026934","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217026934/form4.xml","form_type":"4"}},{"id":4280630,"issuer":{"id":107976,"kind":"organization","name":"BELLICUM PHARMACEUTICALS, INC","symbol":"BLCM"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-15T16:44:41.000Z","date":"2017-06-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest and become exercisable in equal monthly installments until the Issuer's 2018 Annual Meeting of stockholders."}],"balance_after":10000,"derivative":{"exercise_price":10.34,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001358403-17-000101","document":"wf-form4_149755946592701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1358403/000135840317000101/wf-form4_149755946592701.xml","form_type":"4"}},{"id":4415594,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":471,"kind":"person","name":"Stonehouse Jon P","position":1,"cik":"0001385496","reported_name":"Stonehouse Jon P","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Emp. Stock Option (Right to Buy)","published_at":"2017-03-01T18:43:59.000Z","date":"2017-02-27","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant."}],"balance_after":500000,"derivative":{"exercise_price":5.51,"exercise_date":"2018-02-27","expiration_date":"2027-02-27","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001127602-17-009089","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217009089/form4.xml","form_type":"4"}}],"next_cursor":"2017-03-01T18:43:59.000000Z,4415594"}